DCGI gave EUA to Zydus for using Virafin on COVID-19 patients

Drug Controller General of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms.

Daily Current Affairs Quiz 2021

Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery.

For the development of Virafin, Zydus appreciated the support provided by DBT-BIRAC COVID 19 Research Consoritum through NBM, for conducting the Phase II human clinical trial studies.

The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels.

About Zydus Cadila: Also known as Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat.